Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (NCT03681535)
Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
- Radiation Therapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital — Weymouth, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- University of Rochester James P. Wilmot Cancer Institute — Rochester, New York
- Duke University Medical Center — Durham, North Carolina
- MD Anderson Cancer Center — Houston, Texas
- University Hospital Motol — Prague,
- University of Torino — Torino,
- Juntendo University — Tokyo,
- National Cancer Center of Singapore — Singapore,
- Yonsei University Health System — Seoul,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Large B Cell Lymphoma
- Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia — Honolulu, Hawaii
- Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients — Morristown, New Jersey
- Copanlisib Plus Venetoclax in R/R DLBCL — Duarte, California
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers — Basking Ridge, New Jersey
- Split-Dose R-CHOP for Older Adults With DLBCL — Madison, Wisconsin
Explore by condition: All Diffuse Large B Cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.